Over the next 56 weeks, patients reporting nausea steadily decreased to ~8% by the end of the trial
Zuraikat FM, Makarem N, Redline S, Aggarwal B, Jelic S, St-Onge MP (2020) Sleep regularity and cardiometabolic heath: is variability in sleep patterns a risk factor for excess adiposity and glycemic dysregulation
Yes, oral semaglutide (Rybelsus) is available, improving accessibility for patients who prefer not to use injections
GLP-1 and related medications are usually considered for patients with obesity or overweight plus weight-related medical conditions
By following these guidelines, you can enjoy the benefits of GLP-1 RAs improved blood sugar control and significant weight loss while minimizing risks
Additionally, if youre living with obesity and struggling to lose weight, GLP-1s effectively support clinically significant weight loss of more than 10% of body weight